The Covid-19 pandemic has brought the need to develop new medicaments. The pharmaceutical industry has soon begun to develop and test vaccines and drugs against the new virus. The topic of Covid-19 vaccine and the need of vaccination has often been mentioned in the media. Even so, new vaccines are still being developed all around the world. They play a key role in treatment of the infected and pharmaceutical companies are fighting for development of the most effective drug. OZIOS has prepared a summary to introduce how companies are doing on the market.
Vaš retencija će vas kontaktirati za nekoliko minuta s više informacija o ovoj trgovačkoj strategiji.
U.S. companies seized the opportunity to develop Covid-19 vaccine
Gilead Sciences and its Remdesivir
Treatment with Remdesivir has been provided to roughly half of all hospitalized Covid-19 patients in the United States. Even though opinions of scientists on Remdesivir differ, it became the only fully approved drug against Covid-19. Research performed by Market Research Future estimated that the market will reach roughly USD 10,119.99 million till 2027 thanks to the drug developed by Gilead Sciences. In connection with this particular drug, companies such as Mylan, Cipla, Hetero Labs and Jubilant Life Sciences should be mentioned. Gilead Sciences (GILD) became an important part of the healthcare sector including companies such as Amgen Inc. (AMGN) and Johnson & Johnson (JNJ). Current earnings per share of the company rose to 4.1 %. According to Zacks Investment Research, expected profit growth will be 0.81 % in 2021, compared to an industry average of 7.7 %.
Gilead Sciences' performance during last five years. Source: www.investing.com
Eli Lilly and Company and its Bamlanivimab and Etesevimab
The company has newly received authorization of emergency use authorization for bamlanivimab and etesevimab, administered together, to include emergency use as post-exposure prophylaxis for Covid-19. The emergency use is applicable to patients exposed to an individual infected with the SARS-CoV-2 virus or patients who are at high risk of hospitalization. The authorization enables treatment of high-risk patients over 12 years who are not fully vaccinated or who are not expected to mount an adequate immune response to complete vaccination, or have been exposed to an individual infected with SARS-CoV-2, or those who are at high risk of exposure to an individual infected with Covid-19, including the elderly and prisoners. In 2020, Eli Lilly and Company reported total revenues of USD 24.5 billion. The pharmaceutical company recently announced its Q2 results – its revenues exceed, but profits are far from estimates. The year-on-year increase was roughly 23 % and a total revenue rose to $ 6.7 billion.
Performance of Eli Lilly and Company during last 5 years. Source: www.investing.com
Regeneron Pharmaceuticals and its REGEN-COV (casirivimab and imdevimab)
The biotechnology company develops and manufactures drugs for the treatment of serious diseases. The pharmaceutical company is well-known for its Covid-19 drug containing casirivimab and imdevimab. Nowadays, REGEN-COV can be used as a treatment to infected patients in order to reduce the risk of hospitalization or death from Covid-19, and post-exposure prophylaxis for close contact with infected persons. Recently, the company announced an agreement on 1.4 million doses of REGEN-COV with the U.S. government. The vaccines should be ready by the end of January 2022. The cost of approximately USD 2,100 per dose represents roughly USD 2.9 billion in total. Regeneron Pharmaceuticals stocks have risen to 35% during 2021.*
Performance of Regeneron during last 5 years. Source: www.investing.com
Other companies developing Covid-19 drugs
Other important companies developing drugs against the deadly virus are:
· Grifols - global specialized pharmaceutical company based in Spain developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The company develops 7 products against Covid-19 and uses convalescent plasma from recovered Covid-19 donors for direct transfusion.
· Johnson & Johnson
· Tonix Pharmaceuticals
· Novartis
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 0% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Legal information: O.Z.I. Online Zone Investment Opportunities (OZIOS) is a registered brand name of APME FX Trading Europe Ltd, a Cyprus Investment Firm regulated by the Cyprus Securities and Exchange Commission (CySEC) with License No 335/17. The company's registered office address is 21 Kyriakou Oikonomou, 3040, Limassol, Cyprus.
* Past performance is no guarantee of future results.
* Past performance is no guarantee of future results.
* Past performance is no guarantee of future results.
* Past performance is no guarantee of future results.
Izjava o odricanju od odgovornosti:
Ovaj materijal smatra se marketinškom komunikacijom sukladno relevantnim zakonima i propisima i kao takav ne podliježe bilo kojem zabranom trgovanja prije širenja istraživanja ulaganja. Nije pripremljen sukladno pravnim zahtjevima osmišljenim za promicanje neovisnosti istraživanja ulaganja i ne bi se trebao shvatiti kao sadržavajući investicijski savjet, ili preporuku za investiciju, ili ponudu ili traženje bilo kakve transakcije s financijskim instrumentima. Objavljeni sadržaj namijenjen je isključivo edukacijskim/informacijskim svrhama. Ne uzima u obzir financijsku situaciju čitatelja, osobno iskustvo ili investicijske ciljeve. APME FX Trading Europe Ltd ne tvrdi da je pružena informacija točna, aktualna ili potpuna te stoga ne preuzima odgovornost za gubitke koji proizlaze iz ulaganja temeljenih na pruženom sadržaju. Prošla performansa nije jamstvo budućih rezultata.
Chevron otvara put do dosad nedostupnih naslaga na dnu oceana
The Covid-19 pandemic has brought the need to develop new medicaments. The pharmaceutical industry has soon begun to develop and test vaccines and drugs against the new virus. The topic...
Turbulencije u financijskim rezultatima zračnih prijevoznika: Ryanair bilježi veliki pad dobiti
The Covid-19 pandemic has brought the need to develop new medicaments. The pharmaceutical industry has soon begun to develop and test vaccines and drugs against the new virus. The topic...
Vodeći proizvođač IQOS-a lica regulatorni izazovi : je pušenje bez dima stvarno zdravije ?
The Covid-19 pandemic has brought the need to develop new medicaments. The pharmaceutical industry has soon begun to develop and test vaccines and drugs against the new virus. The topic...
Upozorenje na rizik: CFD-ovi su složeni instrumenti i nose visok rizik od brzog gubitka novca zbog poluge. 85.25% računa malih ulagatelja gubi novac prilikom trgovanja CFD-ovima s ovim pružateljem usluga. Trebali biste razmotriti razumijete li kako CFD-ovi funkcioniraju i možete li si priuštiti visok rizik od gubitka novca. Pročitajte naše Izjave o otkrivanju rizika.